David co-founded Enesi Pharma in September 2017 and as CEO as has led the business through a period of rapid growth and establishment to become one of the world’s most exciting companies involved in vaccine delivery and vaccination strategy using Enesi’s ImplaVax® technology, irrespective of target, disease, geography or socioeconomic class.
Prior to Enesi, he was Chief Business Officer of Circassia Pharmaceuticals, and a member of its Senior Management Team with global group responsibility for all M&A, partnering and licensing activities.
Before joining Circassia, David was CEO and co-founder of Prosonix, a particle engineering-enabled respiratory product company, taking it from its establishment in 2006, raising more than £25 million from leading international life sciences investors and institutions over several financing rounds, through to its successful sale in 2015 to Circassia for £100 million.
He has more than 27 years of business development and licensing experience concerning cutting-edge technologies in high growth, complex, IP-rich environments, with a prime focus on the pharmaceutical industry.
David holds a degree in Chemical Engineering from the University of Birmingham, UK